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Abstract A mammalian mutant MAP kinase, D319N ERKZ, analogous to Drosophila melanogaster sevenmaker (rl”“) gain-of-function mutation 
was shown to have an increased sensitivity to low levels of signalling in vivo. However, the mutation does not lead to an elevated basal kinase activity 
and still requires activation by MAP kinase kinase (MAPKK) as does wild type ERKZ. This increased responsiveness seen in vivo is not due to an 
increased ability to phosphorylate substrates but appears to reflect a reduced sensitivity to a MAP kinase phosphatase CLlOO. 
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1. Introduction 
Mitogen-activated protein (MAP) kinases (or extracellular 
signal-related kinases (ERKs)) are serine/threonine protein ki- 
nases that are activated in response to a wide variety of stimuli 
(for recent reviews see [1,2]). They play a pivotal role in the 
regulation of cellular proliferation and differentiation in 
response to extracellular signals acting on receptor tyrosine 
kinases (RTKs). MAP kinase substrates include ~90’“~ [3] 
cytosolic phospholipase A2 [4], MAPKAPK2 [5] as well as 
transcription factors cJun [6], Elk-l [7] and c-Myc [8]. Upon 
activation MAP kinases translocate to the nucleus [9], thus 
phosphorylation of transcription factors by MAP kinase may 
provide a link between extracellular signalling and changes in 
cellular gene expression. However, while MAP kinase activa- 
tion is an attractive mechanism for RTK mediated signal 
transduction in mammalian cells, there is little direct evidence 
that active MAP kinases mediate responses in mammalian cells. 
Much of the genetic analysis of cell<ell interactions medi- 
ated by receptor tyrosine kinases has been carried out in Droso- 
phila melanogaster and Caenorhabditis elegans, which have been 
shown to have signalling pathways with components homolo- 
gous to the vertebrate MAP kinase pathway [lo] and [l 11. In 
Drosophila the correct specification of cell fates at the unseg- 
mented termini of the embryo requires the RTK encoded by the 
gene torso (tor) [ 12,131. The sevenless (sev) gene encodes an- 
other RTK which is required for the specification of the R7 
photoreceptor cell fate in the Drosophila adult eye [14]. Binding 
of its ligand, the product of the bride ofsevenless (boss) gene, 
which is expressed on the surface of the neighbouring R8 pho- 
toreceptor cell activates the sev tyrosine kinase in the R7 pre- 
cursor cell [ 14,151. 
In both of these Drosophila RTK pathways the immediate 
downstream event is activation of the ~21’“” homologue en- 
coded by Dras 1 in Drosophila [ 16,171. Ras activation by RTKs 
occurs both in vertebrates and invertebrates via a SH3-SH2- 
SH3 adaptor protein (Drk/GRB-2) which acts as a link between 
activated RTKs and the Ras guanine nucleotide release factor 
SOS [18,19]. SOS is then able to activate Ras by increasing the 
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rate of exchange of GTP for GDP [20,21]. In mammalian cells 
activated GTP-bound Ras translocates Raf to the plasma mem- 
brane where Raf may undergo further activation [22,23]. Acti- 
vated Raf then leads to the phosphorylation and activation of 
MAP kinase kinase (MAPKK or MEK) [24,25] via phosphoryl- 
ation of MAPKK on two serine residues [26]. MAPKK in turn 
activates MAP kinase by phosphorylation of both a threonine 
and a tyrosine residue [27,28]. 
Recent genetic analysis in Drosophila strongly implies that 
MAP kinase is an effector of the sevenless and torso signalling 
pathways [29]; the identification of loss-of-function mutations 
in the Map kinase rolled locus show that the Drosophila MAP 
kinase homologue, erk-A, is required downstream of Raf in the 
Sev signal transduction pathway [30]. Therefore MAP kinase 
activity appears to be necessary for signalling through the MAP 
kinase pathway. Furthermore, Brunner et al. [29] have identi- 
fied a dominant gain-of-function mutation, known as seven- 
maker, (rl”“) in the Drosophila rl/MAP kinase gene by using 
a genetic screen selecting for mutants which had an activated 
sev signalling pathway in the absence of boss (the RTK ligand 
in the sevenless pathway). This mutation was shown to be a 
single amino acid substitution of the aspartate residue at posi- 
tion 334 into an asparagine residue. This residue is located at 
the C-terminal end of kinase domain XI in the catalytic domain 
of MAP kinase, a region which is conserved among all members 
of the MAP kinase family cloned to date. Sevenmaker activates 
not only the sev pathway but also the tor pathway and some 
developmental pathways controlled by the Drosophila EGF 
receptor homologue (DER) [31]. Thus it appears that MAP 
kinase acts at the end of a conserved signalling cascade used 
by multiple RTKs and that activated MAP kinase is necessary 
and sufficient for signal transduction in the pathway. 
Gain-of-function mutations in MAP kinase would be of great 
value in studying the roles of MAP kinase in signal transduc- 
tion in mammalian cells, in particular to determine whether 
activation of MAP kinase is sufficient for cell proliferation and 
differentiation. Furthermore analysis of the way the single 
point mutation leads to gain-of-function in MAP kinase may 
provide insight into the regulation of the enzyme. In order to 
understand the molecular basis for the gain-of-function and to 
study its effects on signal transduction we have therefore made 
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the analogous sevenmaker mutation in the mammalian MAP 
kinase and have analysed the mechanisms which contribute to 
its increased activity. 
2. Materials and methods 
?. 1. Expression plasmids 
CL100 protein (diluted in 50 mM Tris, pH 7.5, 0.1 mM EGTA, 0.1% 
2-mercaptoethanol, 0.04% Brij 35) for IO min at 30°C. MAP kinase 
activity was then assayed by adding substrate kinase assay buffer (50 
mM Tris 7.5, 0.1 mM EGTA, 0.4 mg/ml MBP or l-2 mg/ml Gst-c-jun 
or Gst-elk-l, 0.5 mM Mg-acetate, 0.125 mM ATP and 63 ,&i/ml “P) 
and incubating for 10 min at 30°C. Incorporation of phosphate into 
MBP was determined as described above. Incorporation of phosphate 
into Gst-c-jun or Gst-elk-l was measured as previously described [37]. 
All constructs for COS-I and NIH cell transfections with the excep- 
tion of pSV2 /?-gal and fos-lcf are based on pEXV3 [32] and with the 
:xception on D319N ERK2myc have been described previously [24]. 
rhe pEXV3-D3 19N ERKZmyc construct was made by mutating codon 
319 of mouse ERK2myc to encode asparagine by site-directed mut- 
igenesis with the Amersham Ml3 kit, sequenced to ensure that there 
were no unwanted mutations and subcloned into pEXV3. pFos Lcf and 
pSV2 /?-galactosidase were the kind gifts of J.L. Bos (University of 
Utrecht, Utrecht, The Netherlands). 
3. Results 
3.1. Gain-of-function of D319N ERK? is not due to constitutive 
activation 
One explanation for the gain-of-function of the sevenmaker 
?.2. GST-fusion proteins 
D319N and wild type murine ERK2 were cloned into pGEXZT, 
:xpression vectors for Gst-elk-l and Gst-c-jun were generous gifts from 
R. Treisman (Imperial Cancer Research Fund, London, UK) and J.R. 
Woodgett (Ontario Cancer Institute, Toronto, Canada), respectively. 
Recombinant proteins were expressed as glutathione-S-transferase fu- 
sion proteins in E. co/i and purified by affinity chromatography on 
;lutathione-Sepharose. ERK2 was cleaved from glutathione-s-trans- 
‘erase with thrombin. Gst-elk-l and Gst-c-Jun were used as intact 
*usion proteins bound to glutathione-Sepharose. Recombinant CL100 
331 protein was the kind gift of S.M. Keyse (Imperial Cancer Research 
Fund, Edinburgh, UK). 
?.3. Transient transfkction of COS cells 
COS-I cells were grown in Dulbecco’s Modified Eagle’s Medium 
:DMEM) containing 10% fetal calf serum (Gibco). Transfection, har- 
jesting and Western blotting of cell lysates was carried out as previously 
described [24]. Immunoprecipitates were assayed for MBP kinase activ- 
ty as previously described [33]. To confirm that equal amounts of 
ERK2 had been immunoprecipitated for each point, precipitated 
ERK2 was run out on a 10% gel and probed with the rabbit polyclonal 
mtibody 122 against ERK2 [34]. 
MAP kinase allele would be constitutive activation of the ki- 
nase in the absence of activation by MAPKK. We therefore 
transiently expressed epitope tagged D319N ERK2 in COS-1 
cells and examined the kinase activity of D319N ERK2 in the 
absence of growth factor stimulation. Western blots of tran- 
siently transfected COS cells showed that D319N ERK2 ran 
with an increased mobility relative to wild type ERK2 in un- 
stimulated cells and upon EGF stimulation both wild type and 
D319N ERK2 shifted to slower migrating phosphorylated 
forms [34]. The shift of D319N was slightly more pronounced 
than with wild type ERK2 (Fig. 1A). Kinase assays of im- 
munoprecipitated D319N ERK2 showed that, in the absence 
of growth factor stimulation, its basal kinase activity was no 
higher than wild type ERK2. EGF stimulated wild type ERK2 
kinase activity increased by 6-fold over that of unstimulated 
cells and D319N showed an 1 l-fold increase (Fig. 1B) which 
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?.4. NIH-3T3 cell transfections 
For transient expression in NIH3T3 cells, cells were grown in 
DMEM containing 10% donor calf serum (Gibco). Transfections were 
:arried out essentially as previously described [35]. Exponentially grow- 
ng cells were seeded at a density of 2 x lo5 cells per 100 mm plate and 
ncubated overnight in growth medium. Then 25 pg of plasmid DNA 
rYas mixed with 0.5 ml of 0.25 M CaCI, and 0.5 ml of 2 x BBS (50 mM 
BES, 280 mM NaCI, 1.5 mM Na,HPO, pH 6.95). The mixture was 
ncubated for 10 min at room temperature. Calcium phosphate-DNA 
solution (1 ml) was added dropwise to the plate of cells and the mixture 
was swirled gently and incubated for 15-20 h at 37°C at 3% CO,. The 
nedium was removed and the cells were rinsed twice with Tris-saline, 
5% donor calf serum, 20 mM HEPES pH 7. I, refed with DMEM + 5% 
DCS and incubated for 5 h. The medium was then changed to 
DMEM + 0.5% DCS and the cells were incubated for a further 48 h 
it 37”C, 10% COz. Cells were lysed using the Promega Luciferase assay 
system lysis buffer. Lysates were assayed for /?-gal expression [36], 
zquilibrated for their p-gal levels to 0.5 U/ml then assayed for luciferase 
evels using the Promega Luciferase assay system. 
_ 
+EGF 
q D319N ERK2 
n Wild type ERK2 
?.5. Assay of MAP kinase activity using recombinant proteins 
Inactive recombinant MAP kinase was activated by incubation with 
:onstitutively active E217/E221 MAPKK [37]. Both enzymes were di- 
.uted in 100 mM Tris-HCI pH 7.5, 0.2 mM Na-EGTA, 0.1% (v/v) 
2-mercaptoethanol (Basic buffer) to give a final assay concentration of 
1.18 mg/ml, MAP kinase, 0.01 mg/ml MAPKK. 20 ~1 of Mg-ATP (0.8 
aM ATP, 40 mM Mg-acetate) was added to 60 ~1 of the diluted MAP 
kinase/MAPKK mix to start the reaction. After 20 min at 30°C the 
reaction was terminated by placing on ice and diluting 1:5 with BSA 
buffer (50 M Tris, pH 7.5, 0.1 mM EGTA, 0.1% 2-mercaptoethanoi, 
I mg/ml BSA). The activated MAP kinase was either used immediately 
3r frozen at 20°C for up to 1 week. For experiments with CLlOO, 
activated MAP kinase was incubated in BSA buffer with purified 
0 2 4 6 8 1012 
Fold Activation 
Fig. 1. Phosphorylation and activation of D319N ERK2. Cell lysates 
were prepared from COS-1 cells transfected (as described in section 2) 
with pEXV3-ERKZmyc or pEXV3-D319N ERKZmyc then stimulated 
with no addition (-) or 2 nM EGF for 10 min prior to cell harvesting 
(+). (A) Transfected ERK2 was detected in cell lysates by western 
blotting as described in section 2. Data essentially identical to these 
have been obtained in at six separate experiments. (B) ERK2myc was 
immunoprecipitated from cell lysates and the MBP kinase activity of 
the immunoprecipitates determined. Data shown are the average of six 
separate experiments. 
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Fig. 2. Kinase assay of recombinant D319N ERK2. D319N ERK2 or 
wild type ERK2 were incubated in the absence (- MAPKK) or presence 
(+MAPKK) of MAPKK as described in section 2. They were then 
assayed for MBP kinase activity. Results above are the average of 
duplicate determinations. Similar results have been obtained in at least 
3 separate xperiments. 
was also reflected in the more pronounced shift (Fig. 1A). To 
further confirm that D319N ERK2 does not have an elevated 
basal kinase activity it was expressed as a GST fusion protein 
in bacteria. The basal activity of recombinant D319N ERK2 
was no higher than wild type and activation of both mutant and 
wild type MAP kinase require phosphorylation by MAPKK. 
Additionally, under these conditions, when phosphorylated by 
MAPKK the levels of kinase activity for recombinant D319N 
and wild type ERK2 are the same (Fig. 2). These results with 
both transient expression in mammalian cells and purified re- 
combinant proteins demonstrate that D319N ERK2 does not 
have elevated basal kinase activity and still responds to growth 
factor stimulation. Thus the gain-of-function resulting from the 
mutation is not a consequence of constitutive activation of the 
kinase. 
3.2. D319N ERk2 is more responsive than wild type ERKZ to 
low levels of signalling 
Since D3 19N ERK2 does not show constitutive activation of 
kinase activity we considered the possibility that its gain-of- 
function results from an increase in its response to signalling. 
Such an idea is attractive given that sevenmaker causes a 
I 
Ras + D319N ERK2 
Ras + WT ERK2 
RAF + D319N ERK2 
I 
RAF+WTERK2 1 c. , , . , , , . , 
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Fig. 3. Potentiation of oncogenic Raf signal by D319N ERKZ. Cell 
lysates were prepared from NIH-3T3 cells transfected as described in 
section 2. Lysates were assayed for luciferase activity. Data shown 
above are the average of duplicate determinations expressed as a per- 
cent of activity with the control plasmid only. 
phenotype that corresponds to those of weak gain-of-function 
mutants in scv and tor RTKs [29]. We therefore decided to turn 
to another system to determine whether D319N ERK2 is better 
able to respond to signals than wild type ERK2. It has been 
previously demonstrated that transfection with oncogenic 
H-Ras or Raf leads to increased expression from the c-fos 
promoter in transient expression systems [38]. We therefore 
investigated whether cotransfection of ERK2 expression plas- 
mids had an effect on c-fos promoter expression stimulated by 
oncogenic Ras or Raf. When transfected alone, wild type 
ERK2 or D3 19N ERK2 had no effect on c-fos driven luciferase 
activity. A striking difference was seen when ERK2 plasmids 
were cotransfected with the oncogenic Raf construct. Onco- 
genie Raf on its own produced a small degree of c-fos promoter 
activation but when cotransfected with D319N ERK2 this acti- 
vation was potentiated 12-fold. In contrast, cotransfection with 
wild type ERK2 produced no potentiation (Fig. 3). The level 
of transcription induced by oncogenic H-Ras increased 4-fold 
when wild type ERK2 was cotransfected. D319N ERK2 in- 
creased the level of H-Ras induced transcription by 2.5-fold, a 
somewhat lesser degree than did wild type. One explanation for 
this may be that the signal generated by H-Ras + wild type 
ERK2 is maximal in this system and that D3 19N under circum- 
stances of strong activation is a less active kinase than is wild 
type. In this system Raf is a poorer activator of the fos pro- 
moter than Ras and thus, with the weaker activation a marked 
difference is seen between the properties of the wild type ERK2 
and the gain-of-function mutant D3 19N. 
One possibility for the increased ability of D3 19N ERK2 to 
activate the c-fos promoter is that its substrate specificity is 
q D319N ERK2 
n Wild type ERKP 
Gst-Elk-l 
bT 
MBP 
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Fig. 4. Phosphorylation of MAP kinase substrates by D319N ERK2. 
Recombinant D319N and wildtype ERK2 were activated and tested (as 
described in section 2) for their ability to phosphorylate (A) Gst-Elk-l, 
(B) MBP and (C) Gst-c-jun in vitro. Results shown are the average of 
triplicate determinations. Error bars represent standard deviation. 
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1:25 
with varying concentrations of CL100 and assayed for kinase 
activity (Fig. 6). Both ERK2 and D319N ERK2 were inac- 
tivated in a dose dependent fashion by CLlOO. However, 
D319N was significantly less susceptible to inactivation. At 0.5 
,f&ml CL100 the D319N ERK2 showed only 53% inactivation 
compared with 80% for the wild type. 
4. Discussion 
q D319N erk2 
w Wild type erk2 
0 20000 40000 60000 
c!w 
Fig. 5. Activation of D319N ERK2 by MAPKK. Recombinant D319N 
and wildtype ERK2 were activated with varying concentrations of
MAPKK as indicated above. The activated ERK2 was tested for its 
ability to phosphorylate MBP in vitro (as described in section 2). Re- 
sults shown are the average of duplicate determinations. Duplicates 
were within 10% of the mean. 
altered or increased. Recently Marais et al. [7] have shown that 
elk- 1, which complexes with SRF transcription factors to regu- 
late c-fos expression, is activated by MAP kinase phosphoryla- 
tion. We therefore examined whether active D319N ERK2 was 
more able than the wild type ERK2 to phosphorylate lk-l in 
vitro. Under the conditions tested, there was very little differ- 
ence in the levels of phosphorylation of elk-l or MBP by active 
D319N ERK2 or wild type ERK2 (Fig. 4a,b). Similarly, an- 
other putative transcription factor substrate, c-jun was also 
phosphorylated no better by D319N than by wild type ERK2 
(Fig. 4~). In fact, all three substrates tested appeared to be 
poorer substrates for the D319N ERK2 than for wild type 
ERK2 which implies that a higher kinase activity toward these 
substrates is not responsible for the gain-of-function properties 
of D319N ERK2. 
The increased responsiveness of D319N ERK2 could be a 
result of its being activated at lower levels of MAPKK than the 
wild type ERK2. To test this hypothesis recombinant ERK2 
and D319N ERK2 were activated with decreasing amounts of 
constitutively active MAPKK in vitro (Fig. 5). Five concentra- 
tions of MAPKK tested did not activate D319N ERK2 to a 
higher level than wild type ERK2, indicating that the difference 
is probably not due to D319N ERK2 being activated by lower 
levels of active MAPKK. 
3.3. D319N ERkY2 shows reduced sensitivity to MAP kinase 
phosphatase 
Since our experiments revealed no constitutive kinase activ- 
ity of D319N ERK2, we explored the possibility that D319N 
ERK2 is less sensitive to negative regulation. Recently it has 
become clear that there is a class of phosphatases which is 
specific for MAP kinases [3941]. The archetype of these 
phosphatases i CL100/3CH134, whose transcription is induci- 
ble with oxidative stress or growth factors [42,43]. Therefore, 
we chose to look at the sensitivity of D319N ERK2 to the 
action of the phosphatase CLlOO. Recombinant ERK2 and 
D319N ERK2 were activated with MAPKK and then treated 
We have shown that the D319N sevenmaker mutation in 
ERK2 does not result in a constitutively active kinase. To 
become activated, mutant ERK2 from COS cell transfections 
or produced in bacteria, requires phosphorylation by MAPKK. 
However in vivo, D319N is more responsive to low levels of 
signalling than is wild type ERK2. Results from cotransfections 
of NIH-3T3 cells show that D319N ERK2 enhances the effect 
of oncogenic Raf while wild type ERK2 has no effect. This 
increased sensitivity to signalling does not appear to be a result 
of increased sensitivity to MAPKK or to an increased ability 
of D319N to phosphorylate substrate. However, the gain-of- 
function mutation D319N is more resistant to the action of a 
MAP kinase phosphatase CL 100. 
Although this mutation was originally isolated from Droso- 
phila which lacked boss, the sev ligand, it is not surprising that 
the gain-of-function is not through constitutive kinase activity. 
The sevenmaker mutation was isolated as a viable mutation 
whereas expression of constitutive mutants of Draf and Dras 
expressed under the control of the heat shock promoter are 
lethal. With the characterization of the rolled/MAP kinase 
locus of Drosophila, the sem mutation/activated MAP kinase 
has been shown to be involved in multiple signalling pathways 
including sev, torso and DER. It therefore might be expected 
that a constitutively activated MAP kinase involved in these 
pathways would lead to a lethal mutation, which would not 
have been seen in the screen for sevenmaker. Although the 
difference in sensitivity to phosphatase inactivation is small, it 
is clear from the genetics of the R7 signalling system [lo] that 
120, 
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Fig. 6. Reduced sensitivity of D319N ERK2 to inactivation by CLlOO. 
Activated recombinant D319N and wild type ERK2 were treated with 
varying concentrations of recombinant CL100 (as described in section 
2) and assayed for their ability to phosphorylate MBP in vitro. Results 
shown above are the average of triplicate determinations. Error bars 
represent standard deviation. Similar results have been obtained in 
three separate experiments. 
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small changes in the dosage of components of the signalling 
pathway can have pronounced effects. Thus a 2-fold difference 
in sensitivity to phosphatase action could well lead to altered 
signalling. It is also possible that reduced sensitivity to phos- 
phatase action is only part of the explanation for why D319N 
ERK2 is more active than wild type ERK. For example there 
may be other substrates for MAP kinase which are differen- 
tially phosphorylated by the sevenmaker mutant which potenti- 
ate the activation of sevenmaker ERK2. 
Although this gain-of-function mutation is not constitutively 
active and therefore does not eliminate the need for upstream 
signals, it may provide insight into downstream events of the 
MAP kinase pathway. In particular, D319N ERK2 may aid in 
the study of MAP kinase specific phosphatases and the role 
which the inactivation of MAP kinase plays in cellular growth 
and differentiation. 
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